Highlights

• Medibank Private (ASX:MPL) 2026 AGM carried all four Shareholder vote items by poll.

• Mike Wilkins AO was re-elected as a director with 96.39% support; Dr Amandeep Hansra was elected as a new director with 99.91% support.

• The 2026 Remuneration Report was adopted with 93.67% of votes in favour, reflecting broad shareholder approval of executive remuneration structures.

• The grant of performance rights to the Chief Executive Officer was approved with 98.45% of votes cast in favour.

Medibank Private Limited (ASX:MPL), Australia's largest private health insurer by policyholder base, held its 2026 Annual General Meeting on 18 November 2026 and carried all four resolutions put to shareholders by way of a poll.

Director Elections

Non-executive director and long-serving board member Mike Wilkins AO was re-elected with 96.39% of poll votes. Dr Amandeep Hansra was proposed for election as a new director; shareholders responded with 99.91% support — one of the highest approval rates of the meeting. Dr Hansra's election brings additional expertise to the Board relevant to Medibank's healthcare strategy and digital health ambitions.

Remuneration Report

The Remuneration Report for the year ended 30 June 2026 was adopted with 93.67% of votes in favour and 6.33% against. The against vote, while elevated relative to some prior years, is below the 25% threshold that would trigger a "first strike" under the two-strikes rule.

CEO Performance Rights

The grant of performance rights to the Chief Executive Officer was approved with 98.45% of votes in favour.

Key Insights

The remuneration report received 93.67% of votes in favour, while the CEO performance rights resolution received 98.45%. All resolutions passed.